Delcath Systems, Inc. (DCTH) — Stock Valuation & Research

Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals…

DCTH key statistics

Explore DCTH's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.